4/24/2012

Incyte and Novartis' blood disorder drug ruxolitinib was recommended for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use an enlarged spleen therapy in myelofibrosis patients. The recommendation will bring Incyte a $40 million milestone payment from Novartis. The drug is called Jakavi in Europe and Jakafi in the U.S., where it was approved by the FDA in November.

Related Summaries